The first word that comes to mind regarding this tactic is "obscene loathsome pharma practice includes extending patents on older drugs by combining them with another one and doubling the price of the original one.  More increases of course follow. Then of course there are drug companies involved in co-promotes that throw up roadblocks to the completion or forward motion of clinical trials. This takes place when they find themselves with a new drug in their pipeline whose market share would be impacted by the co-promote drug.  Ethics and integrity and two unknown words in the industry.

The first word that comes to mind regarding this tactic is "obscene loathsome pharma practice includes extending patents on older drugs by combining them with another one and doubling the price of the original one.  More increases of course follow. Then of course there are drug companies involved in co-promotes that throw up roadblocks to the completion or forward motion of clinical trials. This takes place when they find themselves with a new drug in their pipeline whose market share would be impacted by the co-promote drug.  Ethics and integrity and two unknown words in the industry.

user
no
assistant